Patents by Inventor Larisa Geskin

Larisa Geskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reactive oxygen species production by myeloid-derived suppressor cells as a predictor of patient response to interferon-? therapy
    Patent number: 10627403
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS AS A PREDICTOR OF PATIENT RESPONSE TO INTERFERON-A THERAPY
    Publication number: 20170219585
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Activation of myeloid-derived suppressor cells as a predictor of patient response to interferon-A therapy
    Patent number: 9655950
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 23, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • PREDICTORS OF PATIENT RESPONSE TO INTERFERON-A THERAPY
    Publication number: 20150064136
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: The University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Larisa Geskin, Oleg E. Akilov